Abstract: Olaparib (AZD2281), a pioneering poly(ADP-ribose) polymerase (PARP) inhibitor, has fundamentally transformed the therapeutic landscape for advanced ovarian cancer. By exploiting the concept of synthetic lethality, olaparib selectively targets cancer cells with homologous recombination (HR) deficiency, particularly those harboring BRCA1 or BRCA2 mutations. Extensive clinical trials, including Study 19, SOLO1, SOLO2, and PAOLA-1, have demonstrated its profound efficacy in significantly prolonging progression-free survival in both newly diagnosed and platinum-sensitive relapsed ovarian cancer settings. While olaparib is generally well-tolerated, its clinical utility is challenged by adverse events such as nausea, fatigue, and anemia, as well as the inevitable emergence of acquired resistance through mechanisms like secondary BRCA mutations. Current research is focused on overcoming these limitations by exploring combination therapies with anti-angiogenic agents, PI3K/AKT inhibitors, and immune checkpoint inhibitors, alongside the refinement of HR deficiency biomarkers to optimize patient selection and personalize treatment strategies.
1. Introduction
Ovarian cancer remains the most lethal gynecologic malignancy and a leading cause of cancer-related death in women [85]. Despite high initial response rates to aggressive surgical cytoreduction and platinum-based chemotherapy, up to 80% of women with advanced disease experience tumor progression or recurrence, underscoring the urgent need for novel, targeted therapeutic approaches [85]. Genomic analyses have revealed that approximately 50% of high-grade serous ovarian cancers (HGSOC) exhibit defects in the homologous recombination (HR) DNA repair pathway, most frequently driven by germline or somatic mutations in the BRCA1 and BRCA2 genes [4]. Olaparib (AZD2281, trade name Lynparza) is a first-in-class, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that capitalizes on these inherent DNA repair defects, offering a highly effective targeted therapy for patients with advanced ovarian cancer [4][86].
2. Pharmacological Activity
Olaparib has demonstrated robust clinical efficacy, leading to its approval by the FDA and EMA for multiple ovarian cancer indications [4][86]. In the recurrent disease setting, the randomized Phase II Study 19 trial showed that olaparib maintenance therapy significantly prolonged progression-free survival (PFS) compared to placebo (8.4 versus 4.8 months) in patients with platinum-sensitive relapsed ovarian cancer [13][77]. The Phase III SOLO2 trial confirmed these benefits specifically in BRCA-mutated patients, demonstrating a remarkable PFS of 19.1 months with olaparib versus 5.5 months with placebo [43][83].
Furthermore, olaparib has reshaped first-line treatment paradigms. The landmark SOLO1 trial evaluated olaparib as maintenance therapy in newly diagnosed advanced ovarian cancer patients with BRCA mutations, revealing an unprecedented 70% reduction in the risk of disease progression or death [28][43]. The PAOLA-1 trial expanded its utility beyond BRCA-mutated populations, showing that combining olaparib with the anti-angiogenic agent bevacizumab significantly prolonged PFS in the first-line maintenance setting, particularly for patients testing positive for HR deficiency [30][43]. Olaparib has also been investigated in combination with chemotherapy (e.g., paclitaxel and carboplatin) and other targeted agents like cediranib, showing improved PFS but with distinct and sometimes overlapping toxicity profiles [24][67].
3. Molecular Mechanism of Action
Olaparib functions primarily through the mechanism of "synthetic lethality" [1][13][75]. It is a potent inhibitor of the PARP-1, PARP-2, and PARP-3 enzymes, which are critical for repairing single-strand DNA breaks via the base excision repair (BER) pathway [4][70]. When PARP is inhibited, unrepaired single-strand breaks are converted into highly toxic double-strand breaks during DNA replication [4]. In normal cells, these double-strand breaks are accurately repaired by the HR pathway. However, in cancer cells with HR deficiency (such as those harboring BRCA1/2 mutations), the cells are forced to rely on error-prone repair mechanisms like non-homologous end joining, leading to severe genomic instability and subsequent apoptosis [4][13].
Beyond enzymatic inhibition, olaparib exerts profound cytotoxicity by trapping PARP1 and PARP2 enzymes on the DNA [4][70]. This stabilized PARP-DNA complex physically obstructs replication forks, causing severe cellular damage that is highly lethal to HR-deficient tumor cells [4][81].
4. Structure-Activity Relationship (SAR)
Olaparib (AZD2281 or KU-0059436) was developed from a series of substituted 4-benzyl-2H-phthalazin-1-ones [13]. Its specific chemical structure is 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one [13]. The compound is designed to interact specifically with the NAD+ binding site of PARP enzymes, acting as a competitive inhibitor [43]. In vitro assays demonstrate that olaparib has high affinity and selectivity for its targets, inhibiting PARP-1, PARP-2, and PARP-3 with IC50 values of 5 nM, 1 nM, and 4 nM, respectively, while showing only weak activity against PARP-5a (tankyrase 1) with an IC50 of 1,500 nM [70]. This structural specificity enables its potent nanomolar activity and robust PARP-trapping capabilities [13][70].
5. Current Limitations
Despite its clinical success, olaparib therapy is associated with several limitations. The most frequently reported adverse events include nausea, fatigue, vomiting, and anemia, which can impact patient quality of life and necessitate dose modifications [17][54][87]. Furthermore, combining olaparib with other agents often leads to overlapping toxicities; for instance, its combination with the anti-angiogenic agent cediranib significantly increases the incidence of hypertension, diarrhea, and fatigue, requiring dose reductions in a majority of patients [67].
Acquired resistance to PARP inhibitors is another major clinical challenge. Tumor cells can develop resistance through several mechanisms, most notably secondary restoring mutations in BRCA1 or BRCA2 that re-establish HR proficiency [12]. Other escape mechanisms include the loss of 53BP1 and the functional restoration of Rad51, which allow cancer cells to bypass the DNA repair defects and survive PARP inhibition [84].
6. Future Perspectives
Future research is heavily focused on overcoming PARP inhibitor resistance and expanding the utility of olaparib beyond BRCA-mutated populations. Combination strategies are at the forefront of this effort. Preclinical and clinical studies are investigating the synergy between olaparib and PI3K/AKT pathway inhibitors (such as BKM120 and AZD5363), as PI3K inhibition has been shown to downregulate BRCA expression and sensitize HR-proficient tumors to PARP inhibition [21][36]. Additionally, combinations with immune checkpoint inhibitors (e.g., PD-1/PD-L1 antibodies like durvalumab) are being explored to leverage the interplay between DNA damage and the tumor immune microenvironment [21][39].
Finally, the refinement of homologous recombination deficiency (HRD) diagnostic assays is critical. Developing more comprehensive and accurate biomarkers will help clinicians better identify patients who are most likely to benefit from olaparib, enabling truly personalized treatment strategies in ovarian cancer [30][82].
